Company Profile
Angion Biomedica Stock Price, News & Catalysts
- Ticker:
- ANGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for ANGN.
Company overview
Business overview
Angion Biomedica was a development-stage biotech focused on kidney disease, inflammation, and organ-protection biology. Its story was built around a narrow set of programs trying to create value in hard-to-treat indications.
Geographic Base and Sector Classification
Angion was headquartered in the United States and listed on NASDAQ. It sat in small-cap biotechnology with a translational medicine profile.
Business Model Characteristics
The company depended on clinical progress, target validation, and capital management to keep programs moving. Investors typically focused on early readouts, pipeline prioritization, and whether the biology could support a durable asset.
Position Within the Biotechnology Landscape
Angion occupied a classic small-cap biotech niche where a limited pipeline and limited runway made the stock highly sensitive to data and financing.
Future catalysts
- Angion Biomedica is a legacy / closeout story, with catalysts limited to any residual asset or corporate update. There is no active standalone pipeline driving the name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Angion Biomedica do?
Angion Biomedica was a development-stage biotech focused on kidney disease, inflammation, and organ-protection biology. Its story was built around a narrow set of programs trying to create value in hard-to-treat indications.
On which exchange is ANGN stock listed?
Angion Biomedica (ANGN) is associated with NASDAQ, United States, Biopharma.
What is Angion?
Angion Biomedica is a legacy / closeout story, with catalysts limited to any residual asset or corporate update.
Which conditions is Angion Biomedica targeting with Angion?
Angion Biomedica is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Angion Biomedica describe recent progress with Angion?
Angion Biomedica is a legacy / closeout story, with catalysts limited to any residual asset or corporate update.
What is Biomedica?
Angion Biomedica was a development-stage biotech focused on kidney disease, inflammation, and organ-protection biology.
What should investors watch for with Biomedica?
Angion Biomedica is a legacy / closeout story, with catalysts limited to any residual asset or corporate update.
What is There?
There is no active standalone pipeline driving the name.